David Pérez-Pascual
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David Pérez-Pascual has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Marc Ghigo
Institut Pasteur Université Paris Cité, CNRS UMR 6047, Genetics of Biofilms laboratory, Paris F-75015, France
12 shared publications - José Agustín Guijarro
Área de Microbiología, Departamento de Biología Funcional, Facultad de Medicina, Instituto de Biotecnología de Asturias, Universidad de Oviedo, Oviedo, Spain
7 shared publications - Jessica Méndez
Area de Microbiología, Departamento de Biología Funcional, Facultad de Medicina, IUBA, Universidad de Oviedo, 33006 Oviedo, Asturias, Spain
6 shared publications - Roberto Navais
Área de Microbiología, Departamento de Biología Funcional, Facultad de Medicina, IUBA, Universidad de Oviedo, 33006 Oviedo, Spain
6 shared publications Bianca Audrain
5 shared publications- Eric Duchaud
Université Paris-Saclay, INRAE, UVSQ, VIM
5 shared publications
Latest Publications
- Open Access
- 2 June 2026
- Published by Elsevier in Advances in Nutrition
- Vol. 17 (8) , 100668
Probiotic Human Study Design and Reporting (PRODARE): Recommendations to Improve Research Practice
- 2 June 2026
- Published by Elsevier in Advances in Nutrition
- Vol. 17 (8) , 100668
Open AccessProbiotic Human Study Design and Reporting (PRODARE): Recommendations to Improve Research Practice
- Open Access
- 18 May 2026
- Vol. 7
A Chryseobacterium massiliae pore-forming MACPF domain protein mediates intra and interspecies competition against Bacteroides
Microbiota play crucial roles in host health, including protection against pathogens through competitive interactions between commensal and pathogenic bacteria that are mediated by direct contact or secreted factors. We previously demonstrated that Chryseobacterium massiliae, a zebrafish commensal, protects larvae against infection by Flavobacterium covae (formerly F. columnare). Here, we investigated whether interference interactions contribute to this protective effect. We found that C. massiliae culture supernatant inhibits F. covae growth and a transposon mutagenesis screen identified mutants lacking this activity. All identified mutants carried insertions in a gene encoding a protein homologous to Bacteroidales BSAP pore-forming toxins, characterized by a Membrane Attack Complex/Perforin (MACPF) domain. We showed that this protein, which we named CSAP-1 (for Chryseobacterium Secreted Antimicrobial Protein) displays bactericidal, pore-forming activity that lyses F. covae cells. Unlike BSAP proteins from Bacteroides spp., CSAP-1 displays broader antagonistic activity, targeting multiple species across the Flavobacterium and Chryseobacterium genera—thus mediating interspecies and intergenus inhibition within Bacteroidetes. Although CSAP-1 is not essential for the in vivo protective effect of C. massiliae, administration of purified CSAP-1 alone confers significant protection to zebrafish larvae against sensitive F. covae infection. This study therefore identifies CSAP-1 as the first MACPF protein from C. massiliae with broad-spectrum inhibitory activity against members of the order Flavobacteriales. These findings highlight CSAP-1 as a promising candidate for the development of novel antimicrobial strategies and warrant further mechanistic investigation.
- 18 May 2026
- Vol. 7
Open AccessA Chryseobacterium massiliae pore-forming MACPF domain protein mediates intra and interspecies competition against Bacteroides
Microbiota play crucial roles in host health, including protection against pathogens through competitive interactions between commensal and pathogenic bacteria that are mediated by direct contact or secreted factors. We previously demonstrated that Chryseobacterium massiliae, a zebrafish commensal, protects larvae against infection by Flavobacterium covae (formerly F. columnare). Here, we investigated whether interference interactions contribute to this protective effect. We found that C. massiliae culture supernatant inhibits F. covae growth and a transposon mutagenesis screen identified mutants lacking this activity. All identified mutants carried insertions in a gene encoding a protein homologous to Bacteroidales BSAP pore-forming toxins, characterized by a Membrane Attack Complex/Perforin (MACPF) domain. We showed that this protein, which we named CSAP-1 (for Chryseobacterium Secreted Antimicrobial Protein) displays bactericidal, pore-forming activity that lyses F. covae cells. Unlike BSAP proteins from Bacteroides spp., CSAP-1 displays broader antagonistic activity, targeting multiple species across the Flavobacterium and Chryseobacterium genera—thus mediating interspecies and intergenus inhibition within Bacteroidetes. Although CSAP-1 is not essential for the in vivo protective effect of C. massiliae, administration of purified CSAP-1 alone confers significant protection to zebrafish larvae against sensitive F. covae infection. This study therefore identifies CSAP-1 as the first MACPF protein from C. massiliae with broad-spectrum inhibitory activity against members of the order Flavobacteriales. These findings highlight CSAP-1 as a promising candidate for the development of novel antimicrobial strategies and warrant further mechanistic investigation.
- Open Access
Cross hybridization Inference for Phylogenetic Resolution (CIPHR)-FISH enables microbiome imaging with strain level taxonomic resolution
The spatial organization of microbial communities is a critical determinant of host-microbe interactions, yet species-level mapping remains challenging due to high 16S rRNA sequence homology and spectral crosstalk in multiplexed fluorescence in situ hybridization (FISH). To address this challenge, we developed Cross-hybridization Inference for Phylogenetic Resolution (CIPHR)-FISH, a pipeline that integrates strategic probe design with supervised machine learning. CIPHR-FISH transforms probe cross-hybridization and spectral overlap, traditionally viewed as experimental noise, into informative molecular signatures. Using a gnotobiotic zebrafish model colonized with a defined mix of 10 zebrafish bacterial strains, we trained a support vector machine (SVM) on empirical hybridization patterns from pure bacterial cultures. CIPHR-FISH achieved 99.2 % macro-averaged accuracy, significantly outperforming standard linear unmixing (62.5 %), and successfully discriminated strains with 99.7% sequence homology. Applying this tool to gnotobiotic zebrafish larvae revealed distinct biogeographies: the intestinal bulb hosted highly structured, multi-layered polymicrobial aggregates, while the skin exhibited sparse, uniformly dispersed individual bacterial cells. Notably, we observed significant inter-individual variation in spatial community structure that was obscured by traditional bulk 16S rRNA sequencing. CIPHR-FISH provides a robust, scalable framework for high-resolution spatial biology by converting the limitations of molecular labeling into a rich data source for taxonomic classification. This approach enables the quantification of micro-scale ecological and stochastic forces that shape the microbiome across hosts.
Open AccessCross hybridization Inference for Phylogenetic Resolution (CIPHR)-FISH enables microbiome imaging with strain level taxonomic resolution
The spatial organization of microbial communities is a critical determinant of host-microbe interactions, yet species-level mapping remains challenging due to high 16S rRNA sequence homology and spectral crosstalk in multiplexed fluorescence in situ hybridization (FISH). To address this challenge, we developed Cross-hybridization Inference for Phylogenetic Resolution (CIPHR)-FISH, a pipeline that integrates strategic probe design with supervised machine learning. CIPHR-FISH transforms probe cross-hybridization and spectral overlap, traditionally viewed as experimental noise, into informative molecular signatures. Using a gnotobiotic zebrafish model colonized with a defined mix of 10 zebrafish bacterial strains, we trained a support vector machine (SVM) on empirical hybridization patterns from pure bacterial cultures. CIPHR-FISH achieved 99.2 % macro-averaged accuracy, significantly outperforming standard linear unmixing (62.5 %), and successfully discriminated strains with 99.7% sequence homology. Applying this tool to gnotobiotic zebrafish larvae revealed distinct biogeographies: the intestinal bulb hosted highly structured, multi-layered polymicrobial aggregates, while the skin exhibited sparse, uniformly dispersed individual bacterial cells. Notably, we observed significant inter-individual variation in spatial community structure that was obscured by traditional bulk 16S rRNA sequencing. CIPHR-FISH provides a robust, scalable framework for high-resolution spatial biology by converting the limitations of molecular labeling into a rich data source for taxonomic classification. This approach enables the quantification of micro-scale ecological and stochastic forces that shape the microbiome across hosts.
- Open Access
- 14 January 2026
- Published by Oxford University Press (OUP) in ISME Communications
- Vol. 6 (1)
Cross hybridization inference for phylogenetic resolution-fluorescence in situ hybridization enables microbiome imaging with strain level taxonomic resolution
The spatial organization of microbial communities is a critical determinant of host–microbe interactions, yet species-level mapping remains challenging due to high 16S rRNA sequence homology and spectral crosstalk in multiplexed fluorescence in situ hybridization (FISH). To address this challenge, we developed Cross-hybridization Inference for Phylogenetic Resolution (CIPHR)-FISH, a pipeline that integrates strategic probe design with supervised machine learning. CIPHR-FISH transforms probe cross-hybridization, traditionally viewed as experimental noise, into informative molecular signatures. Using a gnotobiotic zebrafish model colonized with a defined mix of 10 zebrafish bacterial strains, we trained a support vector machine on empirical hybridization patterns from pure bacterial cultures. CIPHR-FISH achieved 99.2% macro-averaged accuracy, significantly outperforming standard linear unmixing (62.5%), and successfully discriminated strains with 99.7% sequence homology. Applying this tool to gnotobiotic zebrafish larvae revealed distinct biogeographies: the intestinal bulb hosted highly structured, multi-layered polymicrobial aggregates, while the skin exhibited sparse, uniformly dispersed individual bacterial cells. Notably, we observed significant variation in spatial community structure that was obscured by traditional bulk 16S rRNA sequencing. CIPHR-FISH provides a robust framework for high-resolution spatial biology by converting the limitations of molecular labeling into a rich data source for taxonomic classification. This approach enables the quantification of micro-scale ecological and stochastic forces that shape the microbiome across hosts.
- 14 January 2026
- Published by Oxford University Press (OUP) in ISME Communications
- Vol. 6 (1)
Open AccessCross hybridization inference for phylogenetic resolution-fluorescence in situ hybridization enables microbiome imaging with strain level taxonomic resolution
The spatial organization of microbial communities is a critical determinant of host–microbe interactions, yet species-level mapping remains challenging due to high 16S rRNA sequence homology and spectral crosstalk in multiplexed fluorescence in situ hybridization (FISH). To address this challenge, we developed Cross-hybridization Inference for Phylogenetic Resolution (CIPHR)-FISH, a pipeline that integrates strategic probe design with supervised machine learning. CIPHR-FISH transforms probe cross-hybridization, traditionally viewed as experimental noise, into informative molecular signatures. Using a gnotobiotic zebrafish model colonized with a defined mix of 10 zebrafish bacterial strains, we trained a support vector machine on empirical hybridization patterns from pure bacterial cultures. CIPHR-FISH achieved 99.2% macro-averaged accuracy, significantly outperforming standard linear unmixing (62.5%), and successfully discriminated strains with 99.7% sequence homology. Applying this tool to gnotobiotic zebrafish larvae revealed distinct biogeographies: the intestinal bulb hosted highly structured, multi-layered polymicrobial aggregates, while the skin exhibited sparse, uniformly dispersed individual bacterial cells. Notably, we observed significant variation in spatial community structure that was obscured by traditional bulk 16S rRNA sequencing. CIPHR-FISH provides a robust framework for high-resolution spatial biology by converting the limitations of molecular labeling into a rich data source for taxonomic classification. This approach enables the quantification of micro-scale ecological and stochastic forces that shape the microbiome across hosts.
- Open Access
A Chryseobacterium massiliae pore-forming MACPF domain protein mediates intra and interspecies competition against Bacteroides
Microbiota play crucial roles in host health, including protection against pathogens through competitive interactions between commensal and pathogenic bacteria that are mediated by direct contact or secreted factors. We previously demonstrated that Chryseobacterium massiliae , a zebrafish commensal, protects larvae against infection by Flavobacterium covae (formerly F. columnare ). Here, we investigated whether interference interactions contribute to this protective effect. We found that C. massiliae culture supernatant inhibits F. covae growth and a transposon mutagenesis screen identified mutants lacking this activity. All identified mutants carried insertions in a gene encoding a protein homologous to Bacteroidales BSAP pore-forming toxins, characterized by a Membrane Attack Complex/Perforin (MACPF) domain. We showed that this protein, which we named CSAP-1 (for Chryseobacterium Secreted Antimicrobial Protein) displays bactericidal, pore-forming activity that lyses F. covae cells. Unlike BSAP proteins from Bacteroides spp., CSAP-1 displays broader antagonistic activity, targeting multiple species across the Flavobacterium and Chryseobacterium genera - thus mediating interspecies and intergenus inhibition within Bacteroidetes . Although CSAP-1 is not essential for the in vivo protective effect of C. massiliae , administration of purified CSAP-1 alone confers significant protection to zebrafish larvae against sensitive F. covae infection. This study therefore identifies CSAP-1 as the first MACPF protein from C. massiliae with broad-spectrum inhibitory activity against members of the order Flavobacteriales . These findings highlight CSAP-1 as a promising candidate for the development of novel antimicrobial strategies and warrant further mechanistic investigation.
Open AccessA Chryseobacterium massiliae pore-forming MACPF domain protein mediates intra and interspecies competition against Bacteroides
Microbiota play crucial roles in host health, including protection against pathogens through competitive interactions between commensal and pathogenic bacteria that are mediated by direct contact or secreted factors. We previously demonstrated that Chryseobacterium massiliae , a zebrafish commensal, protects larvae against infection by Flavobacterium covae (formerly F. columnare ). Here, we investigated whether interference interactions contribute to this protective effect. We found that C. massiliae culture supernatant inhibits F. covae growth and a transposon mutagenesis screen identified mutants lacking this activity. All identified mutants carried insertions in a gene encoding a protein homologous to Bacteroidales BSAP pore-forming toxins, characterized by a Membrane Attack Complex/Perforin (MACPF) domain. We showed that this protein, which we named CSAP-1 (for Chryseobacterium Secreted Antimicrobial Protein) displays bactericidal, pore-forming activity that lyses F. covae cells. Unlike BSAP proteins from Bacteroides spp., CSAP-1 displays broader antagonistic activity, targeting multiple species across the Flavobacterium and Chryseobacterium genera - thus mediating interspecies and intergenus inhibition within Bacteroidetes . Although CSAP-1 is not essential for the in vivo protective effect of C. massiliae , administration of purified CSAP-1 alone confers significant protection to zebrafish larvae against sensitive F. covae infection. This study therefore identifies CSAP-1 as the first MACPF protein from C. massiliae with broad-spectrum inhibitory activity against members of the order Flavobacteriales . These findings highlight CSAP-1 as a promising candidate for the development of novel antimicrobial strategies and warrant further mechanistic investigation.
- Open Access
IL-26 from ILCs regulates early-life gut epithelial homeostasis by shaping microbiota composition
Animals host symbiotic microbial communities that shape gut health. However, how the host immune system and microbiota interact to regulate epithelial homeostasis, particularly during early development, remains unclear. Human interleukin-26 (IL-26) is associated with gut inflammation and has intrinsic bactericidal activity in vitro, yet its in vivo functions are largely unknown, primarily due to its absence in rodents. To examine the role of IL-26 in early life, we used zebrafish and found that gut epithelial cells in il26-/- larvae exhibited increased proliferation and DNA damage, faster turnover, and an altered abundance of cell populations. This epithelial dysregulation occurred independently of the IL-26 canonical receptor and resulted from dysbiosis in il26-/-. Moreover, IL-26 bactericidal activity was conserved in zebrafish. Our findings suggest that IL-26 directly regulates microbiota composition through this property. We further identified innate lymphoid cells (ILCs) as the primary source of IL-26 at this developmental stage. These findings establish IL-26 as a central player in a regulatory circuit linking the microbiota, ILCs, and intestinal epithelial cells to maintain gut homeostasis during early life.
Open AccessIL-26 from ILCs regulates early-life gut epithelial homeostasis by shaping microbiota composition
Animals host symbiotic microbial communities that shape gut health. However, how the host immune system and microbiota interact to regulate epithelial homeostasis, particularly during early development, remains unclear. Human interleukin-26 (IL-26) is associated with gut inflammation and has intrinsic bactericidal activity in vitro, yet its in vivo functions are largely unknown, primarily due to its absence in rodents. To examine the role of IL-26 in early life, we used zebrafish and found that gut epithelial cells in il26-/- larvae exhibited increased proliferation and DNA damage, faster turnover, and an altered abundance of cell populations. This epithelial dysregulation occurred independently of the IL-26 canonical receptor and resulted from dysbiosis in il26-/-. Moreover, IL-26 bactericidal activity was conserved in zebrafish. Our findings suggest that IL-26 directly regulates microbiota composition through this property. We further identified innate lymphoid cells (ILCs) as the primary source of IL-26 at this developmental stage. These findings establish IL-26 as a central player in a regulatory circuit linking the microbiota, ILCs, and intestinal epithelial cells to maintain gut homeostasis during early life.
- 2 December 2023
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 229 (5) , 1546-1556
Analysis of In-Patient Evolution of Escherichia coli Reveals Potential Links to Relapse of Bone and Joint Infections
Bone and joint infections (BJIs) are difficult to treat and affect a growing number of patients, in which relapses are observed in 10-20% of the case. These relapses, which call for prolonged antibiotic treatment and increase resistance emergence risk, may originate from ill understood adaptation of the pathogen to the host. Here, we investigated three pairs of Escherichia coli strains from BJI cases and their relapses to unravel in-patient adaptation. Whole genome comparison presented evidence for positive selection and phenotypic characterization showed that biofilm formation remained unchanged, contrary to what is usually described in such cases. Although virulence was not modified, we identified the loss of two virulence factors contributing to immune system evasion in one of the studied strains. Other strategies, including global growth optimization and colicin production, likely allowed the strains to outcompete competitors. This work highlights the variety of strategies allowing in-patient adaptation in BJIs.
- 2 December 2023
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 229 (5) , 1546-1556
Analysis of In-Patient Evolution of Escherichia coli Reveals Potential Links to Relapse of Bone and Joint Infections
Bone and joint infections (BJIs) are difficult to treat and affect a growing number of patients, in which relapses are observed in 10-20% of the case. These relapses, which call for prolonged antibiotic treatment and increase resistance emergence risk, may originate from ill understood adaptation of the pathogen to the host. Here, we investigated three pairs of Escherichia coli strains from BJI cases and their relapses to unravel in-patient adaptation. Whole genome comparison presented evidence for positive selection and phenotypic characterization showed that biofilm formation remained unchanged, contrary to what is usually described in such cases. Although virulence was not modified, we identified the loss of two virulence factors contributing to immune system evasion in one of the studied strains. Other strategies, including global growth optimization and colicin production, likely allowed the strains to outcompete competitors. This work highlights the variety of strategies allowing in-patient adaptation in BJIs.
- Open Access
- 11 November 2023
- Published by Springer Nature in Microbiome
- Vol. 11 (1) , 1-15
Anti-diarrheal drug loperamide induces dysbiosis in zebrafish microbiota via bacterial inhibition
Background: Perturbations of animal-associated microbiomes from chemical stress can affect host physiology and health. While dysbiosis induced by antibiotic treatments and disease is well known, chemical, nonantibiotic drugs have recently been shown to induce changes in microbiome composition, warranting further exploration. Loperamide is an opioid-receptor agonist widely prescribed for treating acute diarrhea in humans. Loperamide is also used as a tool to study the impact of bowel dysfunction in animal models by inducing constipation, but its effect on host-associated microbiota is poorly characterized.Results: We used conventional and gnotobiotic larval zebrafish models to show that in addition to host-specific effects, loperamide also has anti-bacterial activities that directly induce changes in microbiota diversity. This dysbiosis is due to changes in bacterial colonization, since gnotobiotic zebrafish mono-colonized with bacterial strains sensitive to loperamide are colonized up to 100-fold lower when treated with loperamide. Consistently, the bacterial diversity of gnotobiotic zebrafish colonized by a mix of 5 representative bacterial strains is affected by loperamide treatment.Conclusion: Our results demonstrate that loperamide, in addition to host effects, also induces dysbiosis in a vertebrate model, highlighting that established treatments can have underlooked secondary effects on microbiota structure and function. This study further provides insights for future studies exploring how common medications directly induce changes in host-associated microbiota.Graphical
- 11 November 2023
- Published by Springer Nature in Microbiome
- Vol. 11 (1) , 1-15
Open AccessAnti-diarrheal drug loperamide induces dysbiosis in zebrafish microbiota via bacterial inhibition
Background: Perturbations of animal-associated microbiomes from chemical stress can affect host physiology and health. While dysbiosis induced by antibiotic treatments and disease is well known, chemical, nonantibiotic drugs have recently been shown to induce changes in microbiome composition, warranting further exploration. Loperamide is an opioid-receptor agonist widely prescribed for treating acute diarrhea in humans. Loperamide is also used as a tool to study the impact of bowel dysfunction in animal models by inducing constipation, but its effect on host-associated microbiota is poorly characterized.Results: We used conventional and gnotobiotic larval zebrafish models to show that in addition to host-specific effects, loperamide also has anti-bacterial activities that directly induce changes in microbiota diversity. This dysbiosis is due to changes in bacterial colonization, since gnotobiotic zebrafish mono-colonized with bacterial strains sensitive to loperamide are colonized up to 100-fold lower when treated with loperamide. Consistently, the bacterial diversity of gnotobiotic zebrafish colonized by a mix of 5 representative bacterial strains is affected by loperamide treatment.Conclusion: Our results demonstrate that loperamide, in addition to host effects, also induces dysbiosis in a vertebrate model, highlighting that established treatments can have underlooked secondary effects on microbiota structure and function. This study further provides insights for future studies exploring how common medications directly induce changes in host-associated microbiota.Graphical
- Open Access
Analysis of in-patient evolution of Escherichia coli reveals potential links to relapse of bone and joint infections
Bone and joint infections (BJIs) are difficult to treat and affect a growing number of patients, in which relapses are observed in 10-20% of the case. These relapses, which call for prolonged antibiotic treatment and increase the risk of emergence of resistance, may originate from ill understood adaptation of the pathogen to the host. Here, we studied three pairs of Escherichia coli strains corresponding to three cases of BJIs and their relapse to better understand in-patient adaptation. Whole genome comparison presented evidence for positive selection with prevalence of non-synonymous and loss of function mutations. Phenotypic characterization showed that biofilm formation capacity was not modified, contrary to what is usually described in such relapse cases. Although virulence was not modified, we identified the loss of two virulence factors (namely an AFA afimbrial adhesin and a YadA-like adhesin) contributing to immune system evasion in one of the studied relapse strain. Other selected strategies likely helped the relapse strains to outcompete competitors through global growth optimization and colicin production. This work highlights the variety of strategies allowing in-patient adaptation in BJIs.
Open AccessAnalysis of in-patient evolution of Escherichia coli reveals potential links to relapse of bone and joint infections
Bone and joint infections (BJIs) are difficult to treat and affect a growing number of patients, in which relapses are observed in 10-20% of the case. These relapses, which call for prolonged antibiotic treatment and increase the risk of emergence of resistance, may originate from ill understood adaptation of the pathogen to the host. Here, we studied three pairs of Escherichia coli strains corresponding to three cases of BJIs and their relapse to better understand in-patient adaptation. Whole genome comparison presented evidence for positive selection with prevalence of non-synonymous and loss of function mutations. Phenotypic characterization showed that biofilm formation capacity was not modified, contrary to what is usually described in such relapse cases. Although virulence was not modified, we identified the loss of two virulence factors (namely an AFA afimbrial adhesin and a YadA-like adhesin) contributing to immune system evasion in one of the studied relapse strain. Other selected strategies likely helped the relapse strains to outcompete competitors through global growth optimization and colicin production. This work highlights the variety of strategies allowing in-patient adaptation in BJIs.
- Open Access
Anti-diarrheal drug loperamide induces dysbiosis in zebrafish microbiota via bacterial inhibition
Background Perturbations of animal-associated microbiomes from chemical stress can affect host physiology and health. While dysbiosis induced by antibiotic treatments and disease are well known, chemical, non-antibiotic drugs have recently been shown to induce changes in microbiome composition, warranting further exploration. Loperamide is an opioid-receptor agonist drug widely prescribed drug for treating acute diarrhea in humans. Loperamide is also used as a tool to study the impact of bowel dysfunction in animal models by inducing constipation, but its effect on host-associated microbiota is poorly characterized. Results We used conventional and gnotobiotic larval zebrafish models to show that in addition to host-specific effects, loperamide also has anti-bacterial activities that directly induce changes in microbiota diversity. This dysbiosis is due to changes in bacterial colonization, since germ-free zebrafish mono-reconventionalized with bacterial strains sensitive to loperamide are colonized up to 100-fold lower when treated with loperamide. Consistently, the bacterial diversity of gnotobiotic zebrafish colonized by a mix of representative bacterial strains is affected by loperamide treatment. Conclusion Our results demonstrate that loperamide, in addition to host effects, also induces dysbiosis in a vertebrate model, highlighting that established treatments can have underlooked secondary effects on microbiota structure and function. This study further provides a insights for future studies exploring how common medications directly induce changes in host-associated microbiota.
Open AccessAnti-diarrheal drug loperamide induces dysbiosis in zebrafish microbiota via bacterial inhibition
Background Perturbations of animal-associated microbiomes from chemical stress can affect host physiology and health. While dysbiosis induced by antibiotic treatments and disease are well known, chemical, non-antibiotic drugs have recently been shown to induce changes in microbiome composition, warranting further exploration. Loperamide is an opioid-receptor agonist drug widely prescribed drug for treating acute diarrhea in humans. Loperamide is also used as a tool to study the impact of bowel dysfunction in animal models by inducing constipation, but its effect on host-associated microbiota is poorly characterized. Results We used conventional and gnotobiotic larval zebrafish models to show that in addition to host-specific effects, loperamide also has anti-bacterial activities that directly induce changes in microbiota diversity. This dysbiosis is due to changes in bacterial colonization, since germ-free zebrafish mono-reconventionalized with bacterial strains sensitive to loperamide are colonized up to 100-fold lower when treated with loperamide. Consistently, the bacterial diversity of gnotobiotic zebrafish colonized by a mix of representative bacterial strains is affected by loperamide treatment. Conclusion Our results demonstrate that loperamide, in addition to host effects, also induces dysbiosis in a vertebrate model, highlighting that established treatments can have underlooked secondary effects on microbiota structure and function. This study further provides a insights for future studies exploring how common medications directly induce changes in host-associated microbiota.